{"id":25856,"date":"2023-12-08T18:55:36","date_gmt":"2023-12-08T13:25:36","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=25856"},"modified":"2024-09-17T17:04:07","modified_gmt":"2024-09-17T11:34:07","slug":"american-society-of-hematology-ash-breakthroughs-and-abstracts","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/american-society-of-hematology-ash-breakthroughs-and-abstracts","title":{"rendered":"Unlocking the Future of Hematology: A Sneak Peek into ASH 2023 Discoveries!"},"content":{"rendered":"\n

The upcoming 65th American Society of Hematology (ASH) Annual Meeting and Exposition 2023<\/strong> is just around the corner, and leading pharmaceutical giants like BMS<\/strong>, Genmab<\/strong>, AstraZeneca<\/strong>, Regeneron, BeiGene<\/strong>, ADC Therapeutics<\/strong>, Eli Lilly and Company<\/strong>, Janssen<\/strong>, and others<\/strong> are gearing up for this conference. This conference will provide a platform to highlight the expanding array of treatment options available for blood cancers and disorders. The focus lies on identifying key abstracts that are anticipated to leave a lasting impression, sparking significant interest throughout the event.<\/p>\n\n\n\n

Highlighting the Featured Abstracts at ASH 2023: A Must-See List!<\/strong><\/p>\n\n\n\n

Company<\/strong><\/td>Drug<\/strong><\/td>Trial ID\/ Acronym<\/strong><\/td>Phase<\/strong><\/td>Abstract No.<\/strong><\/td>Abstract Title<\/strong><\/td><\/tr>
Diffuse large B cell lymphoma (DLBCL)<\/strong><\/td><\/tr>
\"C:\\Users\\HP00\\Desktop\\Comapny's<\/strong><\/td>Odronextamab<\/td>NCT03888105 (ELM-2)<\/td>II<\/td>436<\/td>Final Analysis of the Phase 2 ELM-2 Study: Odronextamab in Patients with Relapsed\/Refractory (R\/R) Diffuse Large B-Cell Lymphoma (DLBCL)<\/a><\/strong><\/td><\/tr>
\"C:\\Users\\HP00\\Desktop\\Comapny's<\/strong><\/td>Lisocabtagene maraleucel<\/td>NCT03483103(PILOT)<\/td>II<\/td>105<\/td>Lisocabtagene Maraleucel as Second-Line Therapy for R\/R Large B-Cell Lymphoma in Patients Not Intended for Hematopoietic Stem Cell Transplant: Final Analysis of the Phase 2 PILOT Study<\/td><\/tr>
\"C:\\Users\\HP00\\AppData\\Local\\Microsoft\\Windows\\INetCache\\Content.MSO\\3EB82D25.tmp\"<\/strong><\/td>Epcoritamab + lenalidomide<\/td>NCT05283720 (EPCORE NHL-5)<\/td>II<\/td>438<\/td>Subcutaneous Epcoritamab Plus Lenalidomide in Patients With Relapsed\/Refractory Diffuse Large B-cell Lymphoma from EPCORE NHL-5<\/td><\/tr>
\"C:\\Users\\HP00\\AppData\\Local\\Microsoft\\Windows\\INetCache\\Content.MSO\\6D8E9DBF.tmp\"<\/strong><\/td>Bgb-16673<\/td>NCT05006716<\/td>I\/II<\/td>4401<\/td>First Results from a Phase 1, First-in-Human Study of the Bruton\u2019s Tyrosine Kinase Degrader Bgb-16673 in Patients with Relapsed or Refractory B-Cell Malignancies<\/a><\/strong> (BGB-16673-101)<\/td><\/tr>
\"C:\\Users\\HP00\\AppData\\Local\\Microsoft\\Windows\\INetCache\\Content.MSO\\3EB82D25.tmp\"<\/strong><\/td>Epcoritamab + GemOx<\/td>NCT04663347 (EPCORE NHL-2)<\/td>Ib\/II<\/td>3092<\/td>Epcoritamab SC + GemOx Leads to High Complete Metabolic Response Rates in Patients with Relapsed\/Refractory Diffuse Large B-Cell Lymphoma Ineligible for Autologous Stem Cell Transplant: Updated Results from EPCORE NHL-2<\/td><\/tr>
Epcoritamab + R-mini-CHOP<\/td>4457<\/td>Subcutaneous Epcoritamab + R-mini-CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Ineligible for Full-Dose Anthracycline: Results from the EPCORE NHL-2 Phase 1\/2 Trial. <\/td><\/tr>
Follicular Lymphoma (FL)<\/strong><\/td><\/tr>
\"C:\\Users\\HP00\\AppData\\Local\\Microsoft\\Windows\\INetCache\\Content.MSO\\3EB82D25.tmp\"<\/strong><\/td>Epcoritamab + rituximab + lenalidomide<\/td>NCT05409066 (EPCORE FL-1)<\/td>III<\/td>3053<\/td>EPCORE FL-1: Phase 3 Trial of Subcutaneous Epcoritamab With Rituximab and Lenalidomide (R2) vs R2 Alone in Patients With Relapsed or Refractory Follicular Lymphoma.<\/td><\/tr>
\"C:\\Users\\HP00\\Desktop\\Comapny's<\/strong><\/td>Loncastuximab tesirine + rituximab<\/td>NCT04998669<\/td>II<\/td>984<\/td>Limited Duration Loncastuximab Tesirine with Rituximab Induces High Complete Metabolic Response Rate in High-Risk Relapsed\/Refractory Follicular Lymphoma<\/a><\/strong> \u2013 A Phase 2 Study<\/td><\/tr>
\"C:\\Users\\HP00\\AppData\\Local\\Microsoft\\Windows\\INetCache\\Content.MSO\\3EB82D25.tmp\"<\/strong><\/td>Epcoritamab<\/td>NCT03625037 (EPCORE NHL-1)<\/td>I\/II<\/td>1655<\/td>Epcoritamab SC Monotherapy Drives Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma<\/a><\/strong>: Results from the EPCORE NHL-1 Dose Expansion Cohort.<\/td><\/tr>
\"C:\\Users\\HP00\\Desktop\\Comapny's<\/strong><\/td>Pirtobrutinib <\/td>NCT03740529 (BRUIN)<\/td>I\/II<\/td>3026<\/td>Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed\/Refractory Follicular Lymphoma<\/a><\/strong>: Results from the Phase 1\/2 BRUIN Study<\/td><\/tr>
Multiple Myeloma (MM)<\/strong><\/td><\/tr>
\"C:\\Users\\HP00\\AppData\\Local\\Microsoft\\Windows\\INetCache\\Content.MSO\\CB007F7B.tmp\"<\/strong><\/td>Daratumumab (DARA) + bortezomib, lenalidomide, and dexamethasone <\/td>NCT03710603 (PERSEUS)<\/td>III<\/td>LBA1<\/td>Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial<\/td><\/tr>
\"C:\\Users\\HP00\\AppData\\Local\\Microsoft\\Windows\\INetCache\\Content.MSO\\CB007F7B.tmp\"<\/strong><\/td>Ciltacabtagene autoleucel<\/td>NCT04181827 (CARTITUDE-4)<\/td>III<\/td>1063<\/td>Patient-reported outcomes in the Phase 3 CARTITUDE-4 study of ciltacabtagene autoleucel versus standard of care in patients with lenalidomide-refractory multiple myeloma<\/a><\/strong> after 1-3 lines of therapy<\/td><\/tr>
\"C:\\Users\\HP00\\AppData\\Local\\Microsoft\\Windows\\INetCache\\Content.MSO\\CB007F7B.tmp\"<\/strong><\/td>Daratumumab, bortezomib, melphalan, and prednisone<\/td>NCT03217812 (OCTANS)<\/td>III<\/td>3388<\/td>Daratumumab, bortezomib, melphalan, and prednisone (D-VMP) versus bortezomib, melphalan, and prednisone (V-MP) alone in transplant-ineligible Asian patients with NDMM: final analysis of the Phase 3 OCTANS study<\/td><\/tr>
\"C:\\Users\\HP00\\AppData\\Local\\Microsoft\\Windows\\INetCache\\Content.MSO\\CB007F7B.tmp\"<\/strong><\/td>Daratumumab<\/td>NCT02316106(CENTAURUS)<\/td>II<\/td>210<\/td>Efficacy and safety of daratumumab monotherapy in patients with intermediate-risk or high-risk SMM: final analysis of the Phase 2 CENTAURUS study<\/td><\/tr>
\"C:\\Users\\HP00\\AppData\\Local\\Microsoft\\Windows\\INetCache\\Content.MSO\\6D8E9DBF.tmp\"<\/strong><\/td>Sonrotoclax (BGB-11417) + dexamethasone<\/td>NCT04973605<\/td>Ib\/II<\/td>1011<\/td>Sonrotoclax (BGB-11417) in Combination with Dexamethasone for the Treatment of Relapsed\/Refractory Multiple Myeloma<\/a><\/strong> with t(11;14): Safety, Efficacy, and Determination of Recommended Phase 2 Dose<\/td><\/tr>
\"C:\\Users\\HP00\\AppData\\Local\\Microsoft\\Windows\\INetCache\\Content.MSO\\3EB82D25.tmp\"<\/strong><\/td>GEN3014<\/td>NCT04824794<\/td>I\/II<\/td>4757<\/td>GEN3014 (HexaBody-CD38) in Anti-CD38 mAb\u2013Naive Patients with Relapsed\/Refractory Multiple Myeloma<\/a><\/strong>: Preliminary Results from a Dose-Expansion Cohort of a Phase 1\/2 Trial. <\/td><\/tr>
\"C:\\Users\\HP00\\AppData\\Local\\Microsoft\\Windows\\INetCache\\Content.MSO\\CB007F7B.tmp\"<\/strong><\/td>Talquetamab + pomalidomide<\/td>NCT05050097 (MonumenTAL-2)<\/td>Ib<\/td>1014<\/td>Talquetamab + pomalidomide in patients with RRMM: safety and preliminary efficacy results from the Phase 1b MonumenTAL-2 study<\/td><\/tr>
\"C:\\Users\\HP00\\AppData\\Local\\Microsoft\\Windows\\INetCache\\Content.MSO\\CB007F7B.tmp\"<\/strong><\/td>JNJ-79635322<\/td>NCT05652335<\/td>I<\/td>456<\/td>Characterization of JNJ-79635322, a novel BCMA x GPRC5D x CD3 T-cell redirecting trispecific antibody, for the treatment of multiple myeloma<\/td><\/tr>
\"C:\\Users\\HP00\\Desktop\\Comapny's<\/strong><\/td>BMS-986393<\/td>NCT04674813<\/td>I<\/td>219<\/td>BMS-986393 (CC-95266), a G protein\u2013Coupled Receptor Class C Group 5 Member D (GPRC5D)\u2013Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed\/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 Study<\/td><\/tr>
Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma<\/strong><\/td><\/tr>
\"C:\\Users\\HP00\\AppData\\Local\\Microsoft\\Windows\\INetCache\\Content.MSO\\6D8E9DBF.tmp\"<\/strong><\/td>Sonrotoclax + zanubrutinib<\/td>NCT04277637<\/td>Ia\/Ib<\/td>327<\/td>Combination Treatment with Sonrotoclax (BGB-11417), a Second-Generation BCL2 Inhibitor, and Zanubrutinib, a Bruton Tyrosine Kinase (BTK) Inhibitor, Is Well Tolerated and Achieves Deep Responses in Patients with Treatment-Na\u00efve Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma<\/a><\/strong>: Data from an Ongoing Phase 1\/2 Study<\/td><\/tr>
\"C:\\Users\\HP00\\AppData\\Local\\Microsoft\\Windows\\INetCache\\Content.MSO\\2125C241.tmp\"<\/strong><\/td>Lisaftoclax<\/td>NCT03913949, NCT04494503<\/td>Ib\/II<\/td>1900<\/td>Updated Efficacy and Safety Results of Lisaftoclax (APG-2575) in Patients (pts) with Heavily Pretreated Chronic Lymphocytic Leukemia (CLL)<\/a><\/strong>: Pool Analysis of Two Clinical Trials<\/td><\/tr>
Myelofibrosis<\/strong><\/td><\/tr>
\"C:\\Users\\HP00\\AppData\\Local\\Microsoft\\Windows\\INetCache\\Content.MSO\\C90DFEF7.tmp\"<\/strong><\/td>Selinexor<\/td>NCT04562389  (XPORT-MF-034)<\/td>III<\/td>3209<\/td>A Global, Phase 3, Randomized,
Double-Blind Study to Evaluate Safety  and Efficacy of Selinexor, an XPO-1  Inhibitor in Combination with  ruxolitinib in JAK Inhibitor-Na\u00efve  Myelofibrosis <\/a><\/strong>(XPORT-MF-034)<\/td><\/tr>
\"C:\\Users\\HP00\\AppData\\Local\\Microsoft\\Windows\\INetCache\\Content.MSO\\B8FF7B1D.tmp\"<\/strong><\/td>Pelabresib + ruxolitinib<\/td>NCT04603495<\/td>III<\/td>628<\/td>Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Na\u00efve Patients with Myelofibrosis: Results of the MANIFEST-2 Randomized, Double-Blind, Phase 3 Study<\/td><\/tr>
Mantle cell lymphoma (MCL)<\/strong><\/td><\/tr>
\"C:\\Users\\HP00\\AppData\\Local\\Microsoft\\Windows\\INetCache\\Content.MSO\\7A581833.tmp\"<\/strong><\/td>Ibrutinib + venetoclax<\/td>NCT03112174 (SYMPATICO)<\/td>III<\/td>LBA2<\/td>Ibrutinib Combined with Venetoclax in Patients with Relapsed\/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study<\/td><\/tr>
\"AstraZeneca<\/strong><\/td>Acalabrutinib + venetoclax and rituximab<\/td>NCT05951959 (TrAVeRse)<\/td>II<\/td>3054<\/td>TrAVeRse: A Phase 2, Open-Label, Randomized Study of Acalabrutinib in Combination with Venetoclax and Rituximab in Patients with Treatment- na\u00efve Mantle Cell Lymphoma<\/a><\/strong><\/td><\/tr>
\"C:\\Users\\HP00\\Desktop\\Comapny's<\/strong><\/td>Pirtobrutinib<\/td>NCT03740529(BRUIN)<\/td>I\/II<\/td>981<\/td>Pirtobrutinib in Relapsed\/Refractory (R\/R) Mantle Cell Lymphoma (MCL) Patients with Prior cBTKi: Safety and Efficacy Including High-Risk Subgroup Analyses from the Phase 1\/2 BRUIN Study<\/td><\/tr><\/tbody><\/table><\/figure>\n","protected":false},"excerpt":{"rendered":"

The upcoming 65th American Society of Hematology (ASH) Annual Meeting and Exposition 2023 is just around the corner, and leading pharmaceutical giants like BMS, Genmab, AstraZeneca, Regeneron, BeiGene, ADC Therapeutics, Eli Lilly and Company, Janssen, and others are gearing up for this conference. This conference will provide a platform to highlight the expanding array of […]<\/p>\n","protected":false},"author":14,"featured_media":25859,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[20004,21525,17543,18919,18920,16689,18921],"industry":[17225],"therapeutic_areas":[17233],"class_list":["post-25856","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-american-society-of-hematology","tag-ash-2023","tag-blood-cancer","tag-healthcare-conference","tag-healthcare-event","tag-healthcare-news","tag-hematology","industry-pharmaceutical","therapeutic_areas-hematological-disorders"],"acf":[],"yoast_head":"\nASH 2023 Uncovered: A Glimpse into Breakthroughs and Abstract<\/title>\n<meta name=\"description\" content=\"American Society of Hematology (ASH) Annual Meeting 2023 is around the corner and pharma companies are set to present their key abstract.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/american-society-of-hematology-ash-breakthroughs-and-abstracts\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ASH 2023 Uncovered: A Glimpse into Breakthroughs and Abstract\" \/>\n<meta property=\"og:description\" content=\"American Society of Hematology (ASH) Annual Meeting 2023 is around the corner and pharma companies are set to present their key abstract.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/american-society-of-hematology-ash-breakthroughs-and-abstracts\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-08T13:25:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-17T11:34:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/08182115\/unlocking-the-future-of-hematology-ash-2023-preview.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"10 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"ASH 2023 Uncovered: A Glimpse into Breakthroughs and Abstract","description":"American Society of Hematology (ASH) Annual Meeting 2023 is around the corner and pharma companies are set to present their key abstract.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/american-society-of-hematology-ash-breakthroughs-and-abstracts","og_locale":"en_US","og_type":"article","og_title":"ASH 2023 Uncovered: A Glimpse into Breakthroughs and Abstract","og_description":"American Society of Hematology (ASH) Annual Meeting 2023 is around the corner and pharma companies are set to present their key abstract.","og_url":"https:\/\/www.delveinsight.com\/blog\/american-society-of-hematology-ash-breakthroughs-and-abstracts","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2023-12-08T13:25:36+00:00","article_modified_time":"2024-09-17T11:34:07+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/08182115\/unlocking-the-future-of-hematology-ash-2023-preview.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/american-society-of-hematology-ash-breakthroughs-and-abstracts","url":"https:\/\/www.delveinsight.com\/blog\/american-society-of-hematology-ash-breakthroughs-and-abstracts","name":"ASH 2023 Uncovered: A Glimpse into Breakthroughs and Abstract","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/american-society-of-hematology-ash-breakthroughs-and-abstracts#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/american-society-of-hematology-ash-breakthroughs-and-abstracts#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/08182115\/unlocking-the-future-of-hematology-ash-2023-preview.png","datePublished":"2023-12-08T13:25:36+00:00","dateModified":"2024-09-17T11:34:07+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"American Society of Hematology (ASH) Annual Meeting 2023 is around the corner and pharma companies are set to present their key abstract.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/american-society-of-hematology-ash-breakthroughs-and-abstracts"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/american-society-of-hematology-ash-breakthroughs-and-abstracts#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/08182115\/unlocking-the-future-of-hematology-ash-2023-preview.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/08182115\/unlocking-the-future-of-hematology-ash-2023-preview.png","width":1200,"height":800,"caption":"unlocking-the-future-of-hematology-ash-2023-preview"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/08182115\/unlocking-the-future-of-hematology-ash-2023-preview-300x200.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">American Society of Hematology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">ASH 2023<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Blood Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Healthcare Conference<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Healthcare Event<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Healthcare News<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Hematology<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">American Society of Hematology<\/span>","<span class=\"advgb-post-tax-term\">ASH 2023<\/span>","<span class=\"advgb-post-tax-term\">Blood Cancer<\/span>","<span class=\"advgb-post-tax-term\">Healthcare Conference<\/span>","<span class=\"advgb-post-tax-term\">Healthcare Event<\/span>","<span class=\"advgb-post-tax-term\">Healthcare News<\/span>","<span class=\"advgb-post-tax-term\">Hematology<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Dec 8, 2023","modified":"Updated on Sep 17, 2024"},"absolute_dates_time":{"created":"Posted on Dec 8, 2023 6:55 pm","modified":"Updated on Sep 17, 2024 5:04 pm"},"featured_img_caption":"unlocking-the-future-of-hematology-ash-2023-preview","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/25856","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=25856"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/25856\/revisions"}],"predecessor-version":[{"id":29580,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/25856\/revisions\/29580"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/25859"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=25856"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=25856"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=25856"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=25856"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=25856"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}